CB-1 PULMINIQ™ (cyclosporine, USP) Inhalation Solution Benefit-Risk/Conclusions Stephen Dilly, MD, PhD Chief Medical Officer Chiron | BioPharmaceuticals.

Slides:



Advertisements
Similar presentations
Postmarketing Clinical Studies of A 1 PI Products L. Ross Pierce, M.D. Medical Officer, Clinical Review Branch, Div. of Hematology, FDA.
Advertisements

 Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease:
Discussant Inder Anand, MD, FRCP, D Phil (Oxon.)
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
Purpose To determine whether metoprolol controlled/extended release
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Advances in Lung Transplantation: A Patient Guide David J. Lederer, M.D., M.S. Assistant Professor of Medicine New York Presbyterian Lung Transplant Program.
Critical Appraisal of an Article on Therapy (2). Formulate Clinical Question Patient/ population Intervention Comparison Outcome (s) Women with IBS Alosetron.
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
STICH Mitral Regurgitation Subanalysis Objective Examine the relationship of mitral regurgitation (MR) severity and survival and compare outcomes in patients.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
Entrepreneurial Track, “Developing Your Product” Target Product Profiles Medical & Development Considerations and Challenges Barbara Wirostko, M.D.,
1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.
Prevention of Recurrent Venous Thromboembolism N Engl J Med Apr ;348(15) : PREVENT (Warfarin) Trial.
Rapamune® Cyclosporine Withdrawal in Renal Transplantation Advisory Committee 1/24/02 Rosemary Tiernan, MD, MPH.
1 Ethical issues in clinical trials Bernard Lo, M.D. February 10, 2010.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Successful Concepts Study Rationale Literature Review Study Design Rationale for Intervention Eligibility Criteria Endpoint Measurement Tools.
Landmark Trials: Recommendations for Interpretation and Presentation Julianna Burzynski, PharmD, BCOP, BCPS Heme/Onc Clinical Pharmacy Specialist 11/29/07.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Endocrine and Metabolic Drugs Advisory Committee Meeting - Human Recombinant.
Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 FDA Presentation Advair Diskus 500/50 Carol Bosken, MD, ScM, MPH Medical Officer Division of Pulmonary.
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
C-BR- 1 Raptiva ™ (efalizumab) Benefit:Risk Assessment Charles Johnson, MB, ChB Senior Director Head of Specialty Biotherapeutics Genentech, Inc.
CR-1 Everolimus Benefit/Risk Assessment Howard J. Eisen, MD Thomas J. Vischer Professor of Medicine Chief, Division of Cardiology Drexel University College.
NDA SE-011 Docetaxel FDA Review. FDA Review Team Biostatistics –Clara Chu, PhD. –Gang Chen, PhD. Biopharmaceutics –Safaa Ibrahim PhD –Atiq Rahman,
Background  Certolizumab pegol is a pegylated humanised Fab’ fragment of a monoclonal antibody with high specificity for human TNF α  Phase II studies.
B-1 Pravastatin-Aspirin Combination René Belder, M.D. Executive Director Clinical Design and Evaluation, Metabolics Pharmaceutical Research Institute Bristol-Myers.
Some Design Issues in Microbicide Trials August 20, 2003 Thomas R. Fleming, Ph.D. Professor and Chair of Biostatistics University of Washington FDA Antiviral.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Question 1 Pozen estimated an annual incidence of tardive dyskinesia (TD) of up to 0.038% for metoclopramide at a daily dose of mg/day for 72 days/year.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
1 Markham C. Luke, M.D., Ph.D. Dermatology Clinical Team Leader DDDDP, ODE V, CDER, FDA Combination Topical Products for the Treatment of Acne Vulgaris.
A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.
Copenhagen University Hospital Rigshospitalet, Denmark
Biotechnology Industry Organization (BIO) Risk Management Public Workshop Day 1 - April 9, 2003 Risk Assessment in Drug and Biological Development Joanna.
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
ITFG/IPAC Collaboration BA/BE Technical Team ITFG/IPAC TECHNICAL TEAM: BA/BE IN VITRO AND IN VIVO TESTS Presented by: Stephen Farr, PhD 26 April 2000 Rockville,
1 EXPERIENCES IN EARLY PHASE STUDIES AIMED TO SELECT APPROPRIATE DOSE REGIMENS THAT LED TO SUCCESS VS. FAILURE Naitee Ting, Pfizer Global R&D.
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Regulatory Considerations for Endpoints Ann T. Farrell, M.D. FDA/CDER/DODP.
CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.
Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 OutlineOutline History of development programHistory of development program –Dr. Carol Bosken Introduction.
COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
내과 R2 이지훈 N Engl J Med Sep 8.
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,
Journal Club Leona Isabella von Köckritz.
Conclusion Senior Vice President Medical & Drug Regulatory Affairs Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, Connecticut Manfred Haehl, MD.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
The Stages of a Clinical Trial
Nymox Pivotal Phase 3 Fexapotide (NX-1207) BPH Extension Trial Successfully Meets Primary Endpoint
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
O’Connor Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled.
EMPHASIS-HF Extended Follow-up
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
Addressing Iron Deficiency in Chronic HF
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Niesvizky R et al. Proc ASH 2010;Abstract 619.
These slides highlight an educational report from a late-breaking clinical trials presentation at the 58th Annual Scientific Session of the American College.
Coiffier B et al. Proc ASH 2010;Abstract 857.
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
Daniel Lessler, MD, MHA Chief Medical Officer Health Care Authority
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
The American College of Cardiology Presented by Dr. Timothy Henry
The efficacy and safety of omalizumab in pediatric allergic asthma
New Models of Care in Idiopathic Pulmonary Fibrosis
Late-Breaking Data on LDL-C Reduction
Presentation transcript:

CB-1 PULMINIQ™ (cyclosporine, USP) Inhalation Solution Benefit-Risk/Conclusions Stephen Dilly, MD, PhD Chief Medical Officer Chiron | BioPharmaceuticals

CB-2 The Case for Approval of CyIS Lung transplant is a small, well-defined population Significant unmet need in lung transplantation Strong evidence for benefit –Sound scientific rationale for CyIS –Robust survival advantage Small risk of harm Lung transplant patients will live longer with CyIS, but some outstanding questions remain Approval of CyIS is warranted, with appropriate postapproval commitment

CB-3 The Case for Approval of CyIS Lung transplant is a small, well-defined population Significant unmet need in lung transplantation Strong evidence for benefit –Sound scientific rationale for CyIS –Robust survival advantage Small risk of harm Lung transplant patients will live longer with CyIS, but some outstanding questions remain Approval of CyIS is warranted, with appropriate postapproval commitment

CB-4 The Case for Approval of CyIS Lung transplant is a small, well-defined population Significant unmet need in lung transplantation Strong evidence for benefit –Sound scientific rationale for CyIS –Robust survival advantage Small risk of harm Lung transplant patients will live longer with CyIS, but some outstanding questions remain Approval of CyIS is warranted, with appropriate postapproval commitment

CB-5

CB-6 The Case for Approval of CyIS Lung transplant is a small, well-defined population Significant unmet need in lung transplantation Strong evidence for benefit –Sound scientific rationale for CyIS –Robust survival advantage Small risk of harm Lung transplant patients will live longer with CyIS, but some outstanding questions remain Approval of CyIS is warranted, with appropriate postapproval commitment

CB-7 The Case for Approval of CyIS Lung transplant is a small, well-defined population Significant unmet need in lung transplantation Strong evidence for benefit –Sound scientific rationale for CyIS –Robust survival advantage Small risk of harm Lung transplant patients will live longer with CyIS, but some outstanding questions remain Approval of CyIS is warranted, with appropriate postapproval commitment

CB-8 The Case for Approval of CyIS Lung transplant is a small, well-defined population Significant unmet need in lung transplantation Strong evidence for benefit –Sound scientific rationale for CyIS –Robust survival advantage Small risk of harm Lung transplant patients will live longer with CyIS, but some outstanding questions remain Approval of CyIS is warranted, with appropriate postapproval commitment

CB-9 Postapproval Questions Outstanding questions –How to give CyIS Duration of therapy Practical considerations of delivery –Increase precision of survival benefit Survival, rejection, lung function Optimization of treatment regimen –Further exploration of safety profile Detection of low-frequency safety signals

CB-10 Postapproval Commitment Open-label, multinational study using contemporary prospective matched controls –250 patients treated with CyIS 300 mg CyIS or maximum tolerated dose (MTD), prolonged treatment (5 years) –Placebo control not appropriate or necessary > 1000 matched controls from UNOS database Contemporaneous controls receiving standard-of-care without CyIS Efficacy endpoints –Primary: chronic rejection-free survival –Secondary: all-cause mortality and change in FEV 1 Safety endpoints –Infections requiring hospitalization, renal dysfunction, malignancy

CB-11 Conclusion Lung transplant is a small, well-defined population Significant unmet need in lung transplantation Strong evidence for benefit –Sound scientific rationale for CyIS –Robust survival advantage Small risk of harm Lung transplant patients will live longer with CyIS Outstanding questions can be addressed with a postapproval study Approval of CyIS is appropriate now